We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
Infections can be reduced and patient quality of life can be improved by using antimicrobial wound care materials developed by Pertinax. In vitro studies have already been performed using the company's development across multiple applications.
days to go: Expired investment: £616,916
Thymia aims to empower clinicians with cutting-edge Neuroscience and AI objectively identify and track mental illness using speech, facial movements and behaviour patterns, enabling personalised, efficient treatment and accurate remote monitoring. They have a large dataset, successful sales, and are raising funds for medical regulation, ADHD expansion, and patent filings. 
days to go: Expired investment: £1,126,464
Olberon is a UK based medical device innovations company seeking to raise funds for manufacturing and the sale of Vacuderm which is a device designed to assist with childrens cannulation procedure. Olberon Ltd has already got a strong portfolio of patented medical innovations and two medical devices which are market ready.
days to go: Expired investment: £5,634
A technological healthcare service allowing patients to discuss any concerns with a GP, clinician or specialists via video consultations, home visits, or appointments at the clinic. DocNoc launched less than 12 months ago and has over 160 NHS and private sector doctors and clinics registered on the service. The company's business model is easily flexible and aim to launch DocNoc internationally.
days to go: Expired investment: £269,710
Please watch the video for more information
days to go: Expired investment: £1,210,000
Inspira Pharmaceuticals (IP) is forming a possible new therapy for COVID-19. IP asserts that its in-lab plant-based molecular formulation has killed over 95% of the SARS-CoV-2 virus. The company aims to understand whether a COVID-19 patient can safely inhale the formulation directly into their lungs as an effective treatment. IP has secured cornerstone investment from biotech angel investors and a Singaporean Venture Capitalist (VC) for its formula. IP argues that its technology has the potential for addressing other respiratory infections such as cystic fibrosis, influenza and the common cold in the coming months. The company will use the investment to develop an effective new drug, which will include further laboratory analysis, safety testing, and preparation for human trials.
days to go: Expired investment: £357,179
Active Needle Technology offers an award-winning "needle actuating device" which has high value medical and consumer applications. The company's patent-pending proprietary ultrasonic technology enhances visibility for medical needles in applications such as biopsy, in regional and joint anaesthesia and others. The company aims to commercialise its technology into a $4+ billion special purpose needle market. After identifying obvious commercial advantages in the tattoo market, Active Needle plans to use its ultrasonic needle technology to develop a low-pain tattooing system. Moreover, the company has won an Innovate UK grant to develop and test the tattoo device. With the proceeds, the company will complete CE marking for its initial biopsy device, for development of anaesthesia and tattooing products.

Pitch Rated

81%

Gold

rating powered by

CROWD RATING™

days to go: Expired investment: £194,100
TC BioPharm is an immunotherapy company. It has used its patented technology to harness the power of a particular part of the immune system, Gamma Delta T-cells (GDT), to negate cancer cells in the human body. TC BioPharm has treated terminally ill patients with acute myeloid leukaemia in approved clinical trials garnering positive responses from multiple patients. The company has received regulatory approval from the Medicines and Healthcare products Regulatory Agency (MHRA) to run a COVID-19 clinical trial to address the global pandemic. TC BioPharm aims to use its current technology to provide a frozen product that can be manufactured cost-effectively and distributed globally. The company has already raised over £7 million in the last 15 months. It will use the investment to take its clinical trials forward in COVID-19 and cancer.

Pitch Rated

59%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £1,753,067
Stericile Ltd is a chemical R&D company that has scientifically created a disinfectant meant to combat the epidemic of Hospital Acquired Infections. The company has achieved the biggest technological advancement in the peracetic acid market, having spent over £400,000 to create a unique chemical solution for the healthcare market. Stericile Ltd has secured a UK national supplier that caters to 15,000+ healthcare customers such as dentist & doctor surgeries, care homes, and medical centres with less effective products.
days to go: Expired investment: £229,200
Orthogem is a UK based manufacturer of synthetic bone grafts. Synthetic bone grafts are substitutes for human bone grafts and are designed to replace bone that has been lost. Orthogem have recently started to produce their product in a putty form in order to keep up with the changes in the market. 
days to go: Expired investment: £722,784
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph